INT48336

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 1994
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 4
Total Number 13
Disease Relevance 3.82
Pain Relevance 0.36

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (ARG2) small molecule metabolic process (ARG2) cellular nitrogen compound metabolic process (ARG2)
Anatomy Link Frequency
22RV1 1
iliac artery 1
ARG2 (Homo sapiens)
Pain Link Frequency Relevance Heat
agonist 11 85.88 High High
cytokine 70 66.56 Quite High
tetrodotoxin 1 52.80 Quite High
Potency 1 50.16 Quite High
Inflammation 11 5.00 Very Low Very Low Very Low
bradykinin 11 5.00 Very Low Very Low Very Low
palliative 10 5.00 Very Low Very Low Very Low
antagonist 2 5.00 Very Low Very Low Very Low
aspirin 1 5.00 Very Low Very Low Very Low
Restless leg syndrome 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Cancer 371 96.04 Very High Very High Very High
Malignant Neoplastic Disease 100 95.40 Very High Very High Very High
Stress 9 87.72 High High
Reprotox - General 1 540 87.08 High High
Hyperplasia 40 78.88 Quite High
Hypertension 23 67.44 Quite High
Toxicity 10 63.04 Quite High
Pre-eclampsia 33 61.84 Quite High
Aging 10 24.56 Low Low
Increased Venous Pressure Under Development 15 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
We also observed that androgen deprivation in vitro could decrease ARG2, but not ARG1 protein expression, in LNCaP and 22RV1 cells cultured for seven days in the absence of androgens (Figure 3B).
Negative_regulation (deprivation) of ARG2 in 22RV1
1) Confidence 0.58 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2920336 Disease Relevance 0.62 Pain Relevance 0
The treatment of LNCaP cells with siIL-8 also translated to a decrease in arginase activity (Figure S2B).
Negative_regulation (decrease) of arginase
2) Confidence 0.58 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2920336 Disease Relevance 0.19 Pain Relevance 0.09
Inhibition of either ARG1 or ARG2 resulted in diminished arginase enzymatic activity (Figure 4B).
Negative_regulation (Inhibition) of ARG2
3) Confidence 0.58 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2920336 Disease Relevance 0.48 Pain Relevance 0
The absence of either ARG1 or ARG2 led to higher concentrations of l-arginine in the conditioned media suggesting a lower metabolism of l-arginine by LNCaP cells (Figure 4C).
Negative_regulation (absence) of ARG2
4) Confidence 0.43 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2920336 Disease Relevance 0.37 Pain Relevance 0
The inhibition of either ARG1 or ARG2 translated into increased PBMC proliferation as quantified by BrdU incorporation (Figure 4E, left panel).
Negative_regulation (inhibition) of ARG2
5) Confidence 0.43 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2920336 Disease Relevance 0.14 Pain Relevance 0
These results suggest that ARG1 expression may be more sensitive to AR inhibition than ARG2, whose expression was induced by the agnostic effect of the AR inhibitor.
Negative_regulation (sensitive) of ARG2
6) Confidence 0.42 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2920336 Disease Relevance 0 Pain Relevance 0.04
Inhibition of either ARG1 or ARG2 resulted in diminished arginase enzymatic activity (Figure 4B).
Negative_regulation (diminished) of arginase
7) Confidence 0.42 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2920336 Disease Relevance 0.47 Pain Relevance 0
Furthermore, ARG1 and ARG2 were enzymatically active and their decreased expression by siRNA resulted in reduced overall arginase activity and l-arginine metabolism.
Negative_regulation (reduced) of arginase
8) Confidence 0.37 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC2920336 Disease Relevance 0.64 Pain Relevance 0
This reduced IL-8 production was associated with a reduction of ARG1 and ARG2 24 hrs following R1881 stimulation (Figure 5E).
Negative_regulation (reduction) of ARG2
9) Confidence 0.26 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2920336 Disease Relevance 0.25 Pain Relevance 0.12
Both the ARG1 and ARG2 induction following R1881 stimulation were inhibited by the siRNA treatment, which translated in the absence of an upregulation in arginase activity (Figure 2F).
Negative_regulation (inhibited) of ARG2
10) Confidence 0.19 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2920336 Disease Relevance 0.25 Pain Relevance 0.04
The nitric oxide synthase inhibitor, N omega-nitro-L-arginine (NNA), at 10(-5) M, inhibited the relaxation, but had no significant effect on the spontaneous tension (13.0 +/- 2.6 mN/mm2, P = 0.07).
Negative_regulation (inhibitor) of omega-nitro-L-arginine
11) Confidence 0.10 Published 1994 Journal Dig. Dis. Sci. Section Abstract Doc Link 7512016 Disease Relevance 0.09 Pain Relevance 0.08
Indeed, Wilkinson et al. [17] and Schmitt et al. [18] have demonstrated that intra-arterial infusion of NG-monomethyle-L-arginine (L-NMMA), a NO synthase inhibitor, increased pulse wave velocity (PWV) of iliac artery in animals and humans, respectively, and the effect of acetylcholine, a drug that stimulate endothelial NO production, on PWV was inhibited by coinfusion of L-NMMA.
Negative_regulation (inhibitor) of NG-monomethyle-L-arginine in iliac artery
12) Confidence 0.09 Published 2008 Journal The Open Cardiovascular Medicine Journal Section Body Doc Link PMC2570577 Disease Relevance 0.26 Pain Relevance 0
In dually perfused placental cotyledons several NO inhibitors (N omega-nitro-L-arginine (NOLA), hemoglobin and methylene blue) increase fetal vessel basal perfusion pressure and also increase the constriction induced by the thromboxane mimetic U46619[110].
Neg (NO) Negative_regulation (inhibitors) of omega-nitro-L-arginine
13) Confidence 0.06 Published 2009 Journal Reprod Biol Endocrinol Section Body Doc Link PMC2739214 Disease Relevance 0.06 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox